Seeking Alpha·1d ago
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call TranscriptAnika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Anika Therapeutics appears to be emerging from its 2024 disruption, with revenue growing 15.6% in 2026Q2 to $32.6M across three consecutive quarters of expansion and gross margin rebuilt to 65.1% from just 3.7% in 2024Q3, delivering a 9.1% operating margin and $3.3M of net income — its strongest profitable quarter in…
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 6, 2026 | $0.29-31.0% vs $0.42 | $31M+3.9% vs $29M |
Q3 2026 Jul 29, 2026 | $0.42+1300.0% vs $0.03 | $33M+11.6% vs $29M |
Q2 2026 Apr 29, 2026 | $0.27+485.7% vs -$0.07 | $30M+5.2% vs $28M |
Q1 2026 Feb 26, 2026 | $0.31+348.0% vs -$0.13 | $31M+6.0% vs $29M |
Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
Anika Therapeutics NASDAQ: ANIK reported a 10% increase in third-quarter revenue and raised the lower end of its 2026 revenue and adjusted EBITDA margin forecasts, even as it lowered its commercial channel growth outlook following slower U.S. elective surgery activity.
Anika Therapeutics (ANIK) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.04 per share a year ago.
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM Revenue Secured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM Product Raised Lower End of Full-Year 2026 Total Company Revenue Guidance and Raised 2026 Adjusted EBITDA Guidance BEDFORD, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), the global leader in the design, development, manufacturing and commercialization of hyaluronic acid (HA) innovations, today announced financial results for the third quarter of 2026.
Benchmark ANIK against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Anika Therapeutics, Inc. (ANIK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $14.55 | $194.72M | -110.31 | -5.91% | -1.43% | -1.28% | — | |
| $3.31 | $482.47M | -25.15 | 19.99% | -6.32% | -8.29% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $3.44 | $236.84M | -4.91 | -38.1% | -43.7% | -14.73% | — | |
| $58.54 | $2.98B | 195.98 | 14.88% | 2.52% | 2.93% | — | |
| $100.61 | $6.55B | 25.50 | 0.5% | 17.28% | 21.72% | — |
Anika Therapeutics, Inc. (ANIK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Anika Therapeutics, Inc. (ANIK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 14, 2026·SEC
Jun 23, 2026·SEC
Get notified when ANIK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Anika Therapeutics, Inc. (ANIK) stock FAQ — growth, dividends, profitability & financials explained
Anika Therapeutics, Inc. (ANIK) reported $123.4M in revenue over the trailing twelve months. Revenue was $112.8M in fiscal year 2025. That is 9302% more than the $1.2M of fiscal year 1996.
Anika Therapeutics, Inc. (ANIK) grew revenue by 52.5% over the trailing twelve months, compared with the twelve months before.
No. Anika Therapeutics, Inc. (ANIK) reported a net loss of $1.8M over the trailing twelve months.
Anika Therapeutics, Inc. (ANIK) had a return on equity (ROE) of -1.3% over the trailing twelve months. A negative ROE means the company lost money over the period.
Anika Therapeutics, Inc. (ANIK) generated $2.3M in free cash flow over the trailing twelve months.
